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Received December 12, 2014; accepted May 9, 2015AbstractBackground: We have previously reported that brief pressure overload of the left ventricle reduced myocardial infarct (MI) size. However, the
role of protein kinase C (PKC) remains uncertain. In this study, we investigated whether pressure overload reduces MI size by activating PKC.
Methods: MI was induced by a 40-minute occlusion of the left anterior descending coronary artery and a 3-hour reperfusion in anesthetized
Sprague-Dawley rats. MI size was determined using triphenyl tetrazolium chloride staining. Brief pressure overload was achieved by two 10-
minute partial snarings of the ascending aorta, raising the systolic left ventricular pressure 50% above the baseline value. Ischemic pre-
conditioning was elicited by two 10-minute coronary artery occlusions and 10-minute reperfusions. Dimethyl sulfoxide (vehicle) or calphostin C
(0.1 mg/kg, a specific inhibitor of PKC) was administered intravenously as pretreatment.
Results: The MI size, expressed as the percentage of the area at risk, was significantly reduced in the pressure overload group and the ischemic
preconditioning group (19.0 ± 2.9% and 18.7 ± 3.0% vs. 26.1 ± 2.6% in the control group, where p < 0.001). Pretreatment with calphostin C
significantly limited the protection by pressure overload and ischemic preconditioning (25.2 ± 2.4% and 25.0 ± 2.3%, where p < 0.001).
Calphostin C itself did not significantly affect MI size (25.5 ± 2.4%). Additionally, the hemodynamics, area at risk, and mortality were not
significantly different.
Conclusion: Brief pressure overload of the left ventricle reduced MI size. Since calphostin C significantly limited the decrease of MI size, our
results suggested that brief pressure overload reduces MI size via activation of PKC.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assmyocardial infarct (MI) size.1 The phenomenon of ischemic
preconditioning also suppresses postischemic arrhythmia and
improves myocardial recovery from stunning.2,3 These labo-
ratory findings have been used to inform and enhance strate-
gies to protect human myocardium in cardiac surgery.4e7 To
avoid ischemic insult, several nonischemic maneuvers,
including rapid cardiac pacing,8 heat stress,9 pharmacological
administration,10 and volume overload,11,12 have been devel-
oped to mimic ischemic preconditioning and to protect
myocardium.ociation. All rights reserved.
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extensively investigated. Activation of protein kinase C (PKC)
has been reported to play an important role in ischemic pre-
conditioning protection.12e15 Administration of PKC activa-
tors mimics ischemic preconditioning and decreases MI
size.13,15 Some studies have demonstrated that pretreatment
with PKC inhibitors significantly limits the MI size reduction
caused by ischemic preconditioning.12e15 However, other
studies have reported that administration of PKC inhibitors did
not limit the MI size reduction, and did not support a role of
PKC in ischemic preconditioning protection.16,17
We previously reported that brief pressure overload of the
left ventricle by two episodes of 10-minute partial snaring of
the ascending aorta preconditioned myocardium and signifi-
cantly reduced MI size.18e20 In our previous reports, we
demonstrated that the protective effects of brief pressure
overload is dependent on activation of stress-activated ion
channels, and is independent on activation of adenosine
receptors.18e20 We recently reported that inhibition of
apoptosis plays an important role in the myocardial protection
of left ventricular pressure overload.21 The role of PKC in the
myocardial protection of brief pressure overload is not certain.
Therefore, we conducted this study to investigate whether
brief pressure overload reduces MI size via activation of PKC.
2. Methods
This study was approved by the Animal Experiment
Committee of Taipei Veterans General Hospital, Taipei,
Taiwan. Animals used in this study were cared for humanely
in accordance with the “Guide for the Care and Use of Lab-
oratory Animals” (National Academic Press, 1996).2.1. Animal preparationFig. 1. The experimental protocol. All rats underwent a 40-minute coronary
artery occlusion (CAO) and 3-hour reperfusion (CAR) after different treat-
ments. In the treatment period, Group 1 received no pretreatment except a 10-
minute intravenous infusion of 10% DMSO (dimethyl sulfoxide, vehicle).
Group 2 received two episodes of 10-minute left ventricular pressure overload
(LVPO) by partial snaring of the ascending aorta after infusion of DMSO.
Group 3 received infusion of DMSO followed by ischemic preconditioning by
two episodes of 10-minute coronary artery occlusion and 10-minute reperfu-
sion. Calphostin C (CPS), a specific inhibitor of protein kinase C, was intra-
venously administered in the remaining three groups. Then, Group 4 received
left ventricular pressure overload, Group 5 received ischemic preconditioning,
and Group 6 received no other pretreatment.The techniques of animal preparation have been previously
reported.22,23 Short male Sprague-Dawley rats (250e300 g)
were anesthetized by intraperitoneal pentobarbiturate (30 mg/
kg). After undergoing tracheotomy, each rat was intubated and
ventilated with a ventilator (Harvard Apparatus, South Natick,
MA, USA) with a tidal volume of 0.5e1.5 mL and a respi-
ratory rate of 95e105 breaths per minute. The descending
abdominal aorta was cannulated for arterial pressure moni-
toring. The arterial pressure was measured using a Statham
P23 pressure transducer coupled to a pressure processor
amplifier (Gould Instruments, Cleveland, OH, USA). Elec-
trocardiography leads were placed on the limbs. After median
sternotomy, the heart was exposed. A 4-0 silk suture was
passed around the proximal part of the left anterior descending
coronary artery. The ends of the silk suture were threaded
through a small vinyl tube to form a snare. A ribbon tape was
passed around the ascending aorta. A microtip-manometer
(Millar Inc., Houston, TX, USA) was inserted into the left
ventricle to measure the left ventricular pressure. The arterial
pressure, heart rate, electrocardiography, and left ventricular
pressure were recorded on a pressurized ink-chart recorder
(Gould Instruments, Cleveland, OH, USA) and on a personalcomputer with a waveform data analysis software program
(AcqKnowledge; Biopac System, Goleta, CA, USA). The
body temperature was monitored by a rectal thermometer and
maintained at 37C by heating pads throughout the
experiment.2.2. Experimental protocolAfter hemodynamics were stable for 30 minutes, the rats
were randomly allocated into six groups (Fig. 1). Group 1
received no intervention except a 10-minute intravenous
infusion of 10% dimethyl sulfoxide (DMSO, 0.1 mL/kg,
vehicle; control group). Group 2 received a 10-minute intra-
venous infusion of DMSO followed by brief left ventricular
pressure overload via partial snaring of the ribbon tape around
the ascending aorta to raise the systolic left ventricular pres-
sure 50% above the baseline value for 10 minutes. Two epi-
sodes of this pressure overload were conducted (LVPO group).
Group 3 received a 10-minute intravenous infusion of DMSO
followed by ischemic preconditioning via two episodes of 10-
minute coronary artery occlusion and 10-minute reperfusion
(IPC group). Group 4 received a 10-minute intravenous infu-
sion of calphostin C (0.1 mg/kg, Kyowa Medex, Tokyo,
Japan), a specific inhibitor of PKC,24 10 minutes before left
ventricular pressure overload (CPS-LVPO group). Group 5
received a 10-minute intravenous infusion of calphostin C
10 minutes before ischemic preconditioning (CPS-IPC group).
Group 6 received an intravenous infusion of calphostin C for
10 minutes (CPS-control group). Ten minutes after the above
treatments, an episode of 40-minute coronary artery occlusion
was conducted by pulling the snare around the left anterior
descending coronary artery, which was then fixed by clamping
the vinyl tube with a mosquito clamp. The performance of
successful occlusion was verified by observing the develop-
ment of ST-segment elevation and changes in the QRS com-
plex on the electrocardiography, and cyanotic change of
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nary artery occlusion, the snare was released for reperfusion
for 3 hours. Reperfusion was confirmed by refilling the cor-
onary artery and visualizing a reactive hyperemic response.
No anti-arrhythmic agents were given at any time. The arterial
pressure, heart rate, electrocardiography, and the left ventric-
ular pressure were recorded simultaneously and continuously
throughout the experiments, including baseline (before treat-
ment), treatment period, 40-minute coronary artery occlusion,
and 3-hour reperfusion.2.3. Determination of area at risk and MI sizeThe methods for determination of area at risk (AAR) and
MI size have been previously reported.25,26 At the end of the
experiment, 1000 units of heparin were administered. The
heart was rapidly excised and placed on a perfusion apparatus.
The left anterior descending coronary artery was ligated at the
site of previous occlusion. The ascending aorta was cannulated
(distal to the sinus of Valsalva) and perfused with 1% Evans
blue dye (Sigma-Aldrich, St. Louis, MO, USA). After perfu-
sion was completed, the atria and right ventricular free wall
were removed. The left ventricle plus septum was then cut into
six to seven transverse slices, which were incubated at 37C in
1% triphenyl tetrazolium chloride solution in phosphate buffer
(pH ¼ 7.4) for 20 minutes to visualize MI (area unstained
using triphenyl tetrazolium chloride). The slices were weighed
and fixed in a 10% formalin solution for 24 hours. The basal
surfaces were photographed. Images were traced with a digi-
tizer to calculate both the AAR, identified by Evans blue dye
exclusion, and the MI area. The AAR and MI area of each
heart slice were calculated from planimetry. The percentage of
area of AAR and MI in each heart slice was then multiplied by
the weight of each slice to determine the weights of AAR and
MI in that heart slice. Total weights of AAR and MI were then
calculated and summed for the entire left ventricle plus
septum. AAR was reported as the percentage of left ventricle
plus septum, with MI size as the percentage of AAR.2.4. ChemicalsTable 1Calphostin C (Kyowa Medex, Tokyo, Japan) is a specific
inhibitor of PKC.24 It was dissolved in DMSO at a concen-
tration of 2 mg/mL, and the solution was diluted with steril-
ized water to the concentration of 0.1 mg/mL before use.The mortality and exclusion data.
Group Treatment protocol No. Mortality* No. included2.5. Exclusion criteria
VF HF Other
1 Control 9 1 0 0 8
2 LVPO 9 0 0 0 9
3 IPC 9 0 0 0 9Rats with AAR <10% of the left ventricular weight and rats
exhibiting S-T segment shift on the electrocardiography dur-
ing pressure overload period were excluded.4 CPS-LVPO 9 0 0 0 9
5 CPS-IPC 10 0 0 1 9
6 CPS-Control 9 0 1 0 8
2.6. Statistical analysis* There was no significant difference in the mortality rate among the six
groups. Pearson Chi-square p ¼ 0.688.
CPS ¼ calphostin C; HF ¼ heart failure; IPC ¼ ischemic preconditioning;
LVPO ¼ left ventricular pressure overload; VF ¼ ventricular fibrillation.All values were expressed as mean value ± standard devi-
ation. Hemodynamic variables were analyzed using a one-way
analysis of variance with repeated measures. The differencesin AAR and MI size among groups were analyzed using a one-
way analysis of variance. If the analysis of variance results
were significant, a multiple comparison using a post-hoc
Bonferroni test was made to assess which group was signifi-
cantly different. The analysis of covariance was performed to
evaluate the group difference of MI (expressed as the per-
centage of the left ventricular weight) with AAR (expressed as
the percentage of the left ventricular weight) as covariates.
Differences were considered significant at p < 0.05.
3. Results3.1. Mortality and exclusionsFifty-five rats were used in this study (Table 1). One rat in
Group 1 suffered from ventricular fibrillation and died. One rat
in Group 5 suffered from bleeding from the sternum and hy-
potension during sternotomy. One rat in Group 6 died of heart
failure, which was defined as a progressive decrease of the
systolic arterial pressure <50 mmHg with global left ventric-
ular dilatation and poor contraction. The data for these three
rats were excluded. The mortality rate among the six groups
was not significantly different ( p ¼ 0.688).3.2. Characteristics of brief pressure overloadDuring pressure overload, the systolic left ventricular
pressure increased significantly from 107 ± 9 mmHg to
157 ± 13 mmHg ( p < 0.001), and the systolic arterial
pressure decreased significantly from 107 ± 9 mmHg to
75 ± 5 mm Hg ( p < 0.001) in Group 2 (Table 2). In Group 4,
the systolic left ventricular pressure increased significantly
from 108 ± 9 mmHg to 160 ± 15 mmHg ( p < 0.001),
whereas the systolic arterial pressure decreased significantly
from 108 ± 9 mmHg to 78 ± 10 mmHg ( p < 0.001) during
pressure overload. Thus, the systolic left ventricular pressure
was raised 50% above the baseline value during the pressure
overload period, causing obvious pressure overload of the left
ventricle in Group 2 and Group 4. There was no significant
change of heart rate during the pressure overload period.
After brief pressure overload, the left ventricular pressure,
the arterial pressure and the heart rate returned to baseline
levels.
Table 2
Hemodynamic changes during pressure overload of the left ventricle.
Hemodynamics Baseline 1 LVPO Baseline 2 p
Group 2 (LVPO), n ¼ 9
MAP (mmHg) 76 ± 7 64 ± 6* 77 ± 5 <0.001
SAP (mmHg) 107 ± 9 75 ± 5** 109 ± 9 <0.001
SLVP (mmHg) 107 ± 9 157 ± 13** 109 ± 9 <0.001
HR (beats/min) 429 ± 73 424 ± 55 447 ± 56 0.705
Group 4 (CPS-LVPO), n ¼ 9
MAP (mmHg) 79 ± 6 65 ± 6*** 80 ± 6 <0.01
SAP (mmHg) 108 ± 9 78 ± 10** 107 ± 11 <0.001
SLVP (mmHg) 108 ± 9 160 ± 15** 107 ± 11 <0.001
HR (beats/min) 412 ± 72 427 ± 66 438 ± 66 0.726
Data are presented as mean ± standard deviation. There were significant
changes in MAP, SAP, and SLVP during pressure overload.
* Multiple comparison p < 0.01, as compared with baseline 1.
** Multiple comparison p < 0.001, as compared with baseline 1.
*** Multiple comparison p < 0.05, as compared with baseline 1. There was no
significant change in HR.
Baseline 1 ¼ baseline before left ventricular pressure overload; Baseline
2 ¼ baseline after left ventricular pressure overload; CPS ¼ calphostin C;
HR ¼ heart rate; LVPO ¼ left ventricular pressure overload; MAP ¼ mean
arterial pressure; SAP ¼ systolic arterial pressure; SLVP ¼ systolic left ven-
tricular pressure.
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arterial pressure-heart rate products of the six groups were not
significantly different (Table 3). Treatments before 40-minute
coronary artery occlusion did not elicit any significantTable 3
Hemodynamic changes during the experiments.
Group Treatment protocol No. Baseline 1 Baseline 2
20 m
MAP (mmHg)
1 Control 8 73 ± 6 74 ± 7 68
2 LVPO 9 76 ± 7 77 ± 5 73
3 IPC 9 76 ± 10 75 ± 8 68
4 CPS-LVPO 9 76 ± 9 79 ± 7 73
5 CPS-IPC 9 78 ± 6 76 ± 3 73
6 CPS-Control 8 75 ± 7 77 ± 7 69
HR (beats/min)
1 Control 8 429 ± 42 439 ± 47 424
2 LVPO 9 430 ± 73 447 ± 56 448
3 IPC 9 423 ± 43 444 ± 46 435
4 CPS-LVPO 9 419 ± 63 443 ± 63 436
5 CPS-IPC 9 454 ± 46 455 ± 42 446
6 CPS-Control 8 425 ± 45 433 ± 58 436
PRP (mmHg beats/min/1000)
1 Control 8 31.12 ± 4.36 32.72 ± 5.42 28.95
2 LVPO 9 32.30 ± 5.44 34.45 ± 4.28 32.72
3 IPC 9 31.94 ± 5.66 33.50 ± 5.95 29.77
4 CPS-LVPO 9 32.14 ± 7.19 35.34 ± 6.72 31.73
5 CPS-IPC 9 35.29 ± 4.14 34.55 ± 2.86 32.41
6 CPS-Control 8 31.87 ± 4.82 33.46 ± 6.68 30.49
Data are presented as mean ± standard deviation. There were no significant change
differences in hemodynamic variables among the six groups of animals during ex
Baseline 1 ¼ baseline before treatment; Baseline 2 ¼ baseline after treatment
CPS ¼ calphostin C; HR ¼ heart rate; IPC ¼ ischemic preconditioning; LVPO ¼ l
arterial pressure-heart rate product.hemodynamic changes. There was no significant change in the
arterial pressure and heart rate throughout the experiments,
except during pressure overload of the left ventricle. The he-
modynamic variables among the six groups were not signifi-
cantly different during the experiments.3.4. AAR and MI size analysisThe AAR values, expressed as the percentage of left ven-
tricular weight, of the six groups averaged 50.2 ± 2.6%
(control group), 52.5 ± 3.0% (LVPO group), 51.5 ± 3.4% (IPC
group), 52.8 ± 3.1% (CPS-LVPO group), 51.0 ± 3.3% (CPS-
IPC), and 52.8 ± 2.9% (CPS-control group) (Fig. 2). These
AAR values were not significantly different among the six
groups ( p ¼ 0.416). MI size, expressed as the percentage of
AAR, was 26.1 ± 2.6% in Group 1 (Fig. 2). Pressure overload
significantly reduced MI size in Group 2 (19.0 ± 2.9%,
p < 0.001). Ischemic preconditioning also significantly
decreased MI size in Group 3 (18.7 ± 3.0%, p < 0.001).
Administration of calphostin C significantly limited the
reduction of MI size induced by pressure overload in Group 4
(25.2 ± 2.4%, p < 0.001 vs. Group 2). The MI size reduction
by ischemic preconditioning was also significantly decreased
by pretreatment with calphostin C in Group 5 (25.0 ± 2.3%,
p < 0.001 vs. group 3). Administration of calphostin C itself
did not significantly affect MI size in Group 6 (25.5 ± 2.4%,
p ¼ 0.792 vs. Group 1).
Since AAR is the main determinant of MI size,27 we
performed analysis of covariance with MI size (expressed asCAO CAR
in 40 min 1 h 2 h 3 h
± 5 73 ± 5 73 ± 7 74 ± 7 74 ± 7
± 6 73 ± 7 76 ± 7 75 ± 6 73 ± 7
± 7 77 ± 11 77 ± 10 76 ± 8 73 ± 10
± 4 77 ± 6 75 ± 3 78 ± 4 79 ± 11
± 4 77 ± 7 79 ± 7 79 ± 9 75 ± 4
± 5 78 ± 7 76 ± 5 77 ± 3 73 ± 3
± 55 431 ± 43 449 ± 37 452 ± 61 449 ± 39
± 65 438 ± 54 436 ± 58 428 ± 68 435 ± 70
± 42 442 ± 58 457 ± 39 451 ± 52 439 ± 38
± 72 444 ± 64 428 ± 42 445 ± 63 430 ± 66
± 44 449 ± 44 460 ± 31 461 ± 41 454 ± 42
± 68 455 ± 61 453 ± 58 432 ± 69 433 ± 67
± 4.90 31.51 ± 3.79 32.52 ± 4.13 33.52 ± 6.38 33.42 ± 4.44
± 4.77 31.85 ± 4.72 33.00 ± 3.73 32.04 ± 5.05 31.67 ± 5.96
± 4.47 34.07 ± 7.84 35.06 ± 5.38 33.99 ± 4.45 31.93 ± 4.64
± 5.34 34.02 ± 5.19 32.05 ± 2.42 34.92 ± 5.79 34.28 ± 7.47
± 2.96 34.44 ± 4.88 36.18 ± 2.12 36.28 ± 4.72 34.00 ± 3.08
± 6.42 35.39 ± 6.84 34.39 ± 4.07 33.13 ± 5.12 31.29 ± 4.52
s in MAP, HR, and PRP throughout the experiment. There were no significant
periments.
; CAO ¼ coronary artery occlusion; CAR ¼ coronary artery reperfusion;
eft ventricular pressure overload; MAP ¼ mean arterial pressure; PRP ¼ mean
Fig. 2. (A) Size of area at risk (AAR), expressed as a percentage of the left ventricle (LV); (B) size of myocardial infarct (MI), expressed as a percentage of AAR.
*p < 0.001 versus Group 1. **p < 0.001 versus Group 2. ***p < 0.001 versus Group 3.
Fig. 3. Myocardial infarct (MI) size was plotted as a function of area at risk
(AAR). Both MI and AAR were expressed as the percentage of left ventricular
(LV) weight. “ ”, regression line of Group 1 (control group,
“-”, “MI/LV ¼ 0.33þ0.23*AAR/LV”, p ¼ 0.226, R2 ¼ 0.23).
“ ”, regression line of Group 2 (LVPO group, “B”, “MI/
LV ¼ 10.64þ0.35*AAR/LV”, p ¼ 0.017, R2 ¼ 0.58). “ ”,
regression line of Group 3 (IPC group, “,”, “MI/LV ¼ 1.16þ0.18*AAR/
LV”, p ¼ 0.395, R2 ¼ 0.10). “ ”, regression line of Group 4
(CPS-LVPO group, “A”, “MI/LV ¼ 6.60þ0.08*AAR/LV”, p ¼ 0.684,
R2 ¼ 0.03). “ ”, regression line of Group 5 (CPS-IPC group,
“:”, “MI/LV ¼ 0.74þ0.19*AAR/LV”, p ¼ 0.175, R2 ¼ 0.25).
“ ”, regression line of Group 6 (CPS-control group, “C”, “MI/
LV ¼ 2.99þ0.15*AAR/LV”, p ¼ 0.557, R2 ¼ 0.06). The slopes of the
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variable and AAR (expressed as the percentage of left ven-
tricular weight) as a covariate to determine the effect of AAR
on MI size. The data points and the regression line of each
group are shown in Fig. 3. After adjusting MI for AAR,
analysis of covariance showed that the regression lines for
MI/LV for the control group, CPS-LVPO group, CPS-IPC
group, and CPS-control group were not significantly
different. However, the regression lines for MI/LV for the
LVPO group and the IPC group were significantly different
from those of the control group, CPS-LVPO group, CPS-IPC
group, and CPS-control group ( p < 0.001). The results
demonstrated that pressure overload and ischemic pre-
conditioning reduced MI size and that the protective effects
of pressure overload and ischemic preconditioning were
dependent upon activation of PKC.
4. Discussion
In the current study, we demonstrated that brief pressure
overload of the left ventricle by two episodes of partial snaring
of the ascending aorta, raising the systolic left ventricular
pressure 50% above the baseline value, significantly reduced
MI size in anesthetized rats. The myocardial protective effects
were comparable to those of ischemic preconditioning (Fig. 2).
There were no significant hemodynamic changes during the
experiments (Table 3), so the reduction of MI size could not be
ascribed to hemodynamic changes. Although the underlying
mechanisms are not certain, administration of calphostin C, a
specific inhibitor of PKC,24 significantly limited the MI size
reduction. Our results suggested that brief left ventricular
pressure overload might reduce MI size via activation of PKC.
PKC has been reported to play an important role in
myocardial protection.12e15 It has been shown that ischemic
preconditioning activates PKC by translocation of inactive
cytosolic PKC to particulate fractions, where the kinase ac-
tivity of PKC occurs.28e30 Administration of PKC activators
mimics ischemic preconditioning and reduces MI size in
rabbits and rats.13,15 Pretreatment with PKC inhibitorsprevents the protection induced by ischemic pre-
conditioning.12e15 However, Przyklenk et al16 reported that
PKC inhibitors did not prevent the MI size reduction by
ischemic preconditioning, and that ischemic preconditioning
did not to induce translocation of PKC in dogs. Vahlhaus
et al17 demonstrated that PKC inhibitors did not prevent
ischemic preconditioning protection in swine. Although there
are discrepancies among the effects of PKC inhibitors on MI
size reduction by ischemic preconditioning, our resultsregression equations of the six groups were not significantly different.
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myocardial protection by brief pressure overload.
We previously reported that administration of gadolinium, a
blocker of stretch-activated ion channels, significantly limits
the MI size reduction by brief pressure overload and ischemic
preconditioning. Both brief pressure overload and ischemic
preconditioning may share activation of stretch-activated ion
channels as common mechanisms.19 It has been shown that
ischemic preconditioning protects the myocardium via activa-
tion of adenosine receptors.10,12,18,20 We demonstrated that
brief pressure overload reduces MI size independent of acti-
vation of adenosine receptors in rabbits and rats.18,20 Brief
pressure overload might protect the myocardium through some
pathways different from ischemic preconditioning. Although
PKC plays an important role in ischemic preconditioning,12e15
the role of PKC in brief pressure overload protection is not fully
understood. In this study, we demonstrated that brief pressure
overload reduces MI size dependent on activation of PKC.
In contrast to our finding that activation of PKC mediates
myocardial protection by brief left ventricular pressure
overload, activation of PKC has been reported to contribute to
hypertrophy and heart failure after chronic pressure over-
load.31 Bayer et al32 reported that supra-renal abdominal
aorta constriction in rats induced hypertension, left ventric-
ular hypertension, and heart failure over time. Increased
expression and phosphorylation of various PKC isoenzymes
were found. Liu et al33 reported that transgenic PKCa-dele-
tion mice were less susceptible to heart failure following
chronic pressure overload induced by transverse aortic arch
constriction. They also demonstrated that administration of a
PKC inhibitor, ruboxistaurin, prevented death in wild-type
mice throughout 10 weeks of chronic pressure overload.
Reduced ventricular dilation, enhanced ventricular perfor-
mance, reduced fibrosis, and decreased pulmonary edema
were also found. Accordingly, they suggested that PKC in-
hibitors might represent a novel therapeutic approach in
treating heart failure.
Brief myocardial stretch has been shown to induce
myocardial protection. We stretched myocardium by pressure
overload of the left ventricle in this study. Ovize et al11 re-
ported that rapid infusion of normal saline, which they
described as “volume overload,” significantly reduced MI size.
Gysembergh et al12 demonstrated that infusion of a PKC in-
hibitor significantly decreased the MI size reduction by vol-
ume overload. In the current study, we demonstrated that
calphostin C, a specific inhibitor of PKC, significantly limited
the reduction of MI size induced by pressure overload. Acti-
vation of PKC may mediate the myocardial protective effects
of both pressure overload and volume overload.
There were limitations in this study. Firstly, there were
several PKC isoforms,34,35 and the effects of specific PKC
isoforms were not examined in our study. Calphostin C, a
specific inhibitor of PKC,24 was used in this study. However,
the expression of PKC itself was not examined in this study.
The effects of pressure overload and calphostin C on
myocardial blood flow were not determined. The performance
of successful coronary artery occlusions was verified byobserving the development of ST-segment elevation and
changes in the QRS complex on electrocardiography, and
cyanotic change of myocardium in the occluded area. No
definite myocardial blood flow data were collected.
However, rats have a limited collateral coronary circulation,36
and our model is comparable to that widely used in
experiments on myocardial ischemia and pre-
conditioning.2,9,14,15,20,21,25e27,29,30,32 The current study was
conducted on anesthetized, open-chest rats. The acute effects
of anesthesia and surgery should be taken into account when
interpreting the results.37 Although triphenyl tetrazolium
chloride staining technique is commonly used to determine MI
size, the infarct size might have been underestimated.38
In conclusion, brief pressure overload of the left ventricle
significantly reduced MI size. The MI size reduction was
significantly limited by administration of calphostin C, a
specific PKC inhibitor. Our results suggested that brief pres-
sure overload might reduce MI size via activation of PKC.
Further studies are required to investigate the underlying
mechanisms and signal transduction pathways involved.
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